Healthcare / Health Information ServicesUpdated 2026-05-10 22:07 UTC

TXG stock hub

10x Genomics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TXGis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

2.7B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

TXG

In the news

Latest news · TXG

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-3

P25 -105.6P50 -46.5P75 -3.1

ROIC-5.1

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TXG market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

226

Groups with data

Currency

USD

Showing 226 of 226 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001770787
Company name	10x Genomics, Inc.
Country	United States
Country code	US
Cusip	88025U109
Employees	1,178
Employees Change	-128%
Employees Change Percent	-9.8
Enterprise value	$2.3B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Health Information Services
IPO Date	2019-09-12
Isin	US88025U1097
Last refreshed	2026-05-10
Market cap	$2.7B
Market cap category	Mid-Cap
Price	$21.6
Price currency	USD
Rev Per Employee	542,260.61x
Sector	Healthcare
Sic	3826
Symbol	TXG
Website	https://www.10xgenomics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-0.83%
EV Sales Forward	3.69x
EV/FCF	18.69x
EV/Sales	3.58x
FCF yield	4.46%
P/B ratio	3.42x
P/S ratio	4.29x
PS Forward	4.43x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-10.77%
EBITDA Margin	-4.8%
FCF margin	19.13%
Gross margin	69.68%
Gross Profit	$445.1M
Gross Profit Growth	4.31%
Gross Profit Growth Q	0.7%
Gross Profit Growth3 Y	3.14%
Gross Profit Growth5 Y	10.68%
Net Income	$-22.7M
Net Income Growth Quarters	5%
Net Income Growth Years	2%
Pretax Margin	-3.01%
Profit Margin	-3.55%
Profit Per Employee	$-19,233
ROA	-4.48
Roa5y	-9.03
ROCE	-7.63
ROE	-2.98
Roe5y	-18.37
ROIC	-5.11

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	160.1%
Cagr3y	-26.44%
Cagr5y	-31.8%
EPS Growth Quarters	5
EPS Growth Years	2
FCF Growth	169.33%
FCF Growth Q	-24.45%
OCF Growth	125.27%
OCF Growth Q	-23.96%
Revenue Growth	2.26x
Revenue Growth Q	-2.61x
Revenue Growth Years	1x
Revenue Growth3 Y	6.01x
Revenue Growth5 Y	13.93x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.67
Assets	$1B
Cash	$539.8M
Current Assets	$669.7M
Current Liabilities	$113.6M
Debt	$81.4M
Debt Equity	$0.1
Debt FCF	$0.67
Equity	$814.3M
Liabilities	$201.4M
Long Term Assets	$346M
Long Term Liabilities	$87.8M
Net Cash	$458.5M
Net Cash By Market Cap	$16.72
Net Cash Growth	32.19%
Net Debt Equity	$-0.56
Net Debt FCF	$-3.75
Tangible Book Value	$749.9M
Tangible Book Value Per Share	$5.81
WACC	15.08

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.9
Inventory Turnover	3.02
Net Working Capital	$27.6M
Quick ratio	5.25
Working Capital	$556.1M
Working Capital Turnover	$1.24

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-4.06%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	159.93%
200-day SMA	17.18
3Y total return	-60.2%
50-day SMA	21.56
50-day SMA vs 200-day SMA	50over200
5Y total return	-85.24%
All Time High	209
All Time High Change	-89.66%
All Time High Date	2021-06-29
All Time Low	6.78
All Time Low Change	218.58%
All Time Low Date	2025-04-07
ATR	1.45
Beta	2.05
Beta1y	1.9
Beta2y	1.47
Ch YTD	32.43
High	21.99
High52	26.45
High52 Date	2026-04-17
High52ch	-18.32%
Low	19.82
Low52	8.07
Low52 Date	2025-05-23
Low52ch	167.82%
Ma50ch	0.19%
Premarket Change Percent	-7.72
Premarket Price	$20.69
Premarket Volume	11,728
Price vs 200-day SMA	25.72%
RSI	47.28
RSI Monthly	48.17
RSI Weekly	55.32
Sharpe ratio	1.69x
Sortino ratio	2.98
Total Return	-4.06%
Tr YTD	32.43
Tr1m	-1.01%
Tr1w	-3.7%
Tr3m	16.07%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	15
Analyst Count Top	2
Analyst Price Target Top	$22
Analyst Ratings	Hold
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.1
Earnings Revenue Estimate	146,381,144x
Earnings Revenue Estimate Growth	-5.49x
Operating Income	$-68.8M
Operating margin	-10.77
Price target	$20.25
Price Target Change	$-6.25
Price Target Change Top	$1.85

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	115,087,465%
Float Percent	90.65%
Shares Insiders	7.82%
Shares Institutions	99.3%
Shares Out	126,956,189
Shares Qo Q	0.95%
Shares Yo Y	4.06%
Short Float	14.31%
Short Ratio	6.84
Short Shares	12.98

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$21.5M
Average Volume	2,764,043.25x
Bv Per Share	6.31
CAPEX	$-5.6M
Ch1m	-1.01
Ch1w	-3.7
Ch1y	159.9
Ch3m	16.07
Ch3y	-60.2
Ch5y	-85.24
Ch6m	41.64
Change	-3.66%
Change From Open	2.52
Close	22.42
Days Gap	-6.02
Depreciation Amortization	38,134,000
Dollar Volume	104,363,078.4
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-68.8M
EBITDA	$-30.7M
EPS	$-0.18
F Score	4
FCF	$122.2M
FCF EV Yield	5.35x
FCF Per Share	$0.96
Financing CF	-2,036,000
Fiscal Year End	December
Founded	2,012
Goodwill	4,511,000
Income Tax	$3.4M
Investing CF	-12,856,000
Ipr	-44.62
Iprfo	-60
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-13
Ma150	18.51
Ma150ch	16.69%
Ma20	22.89
Ma20ch	-5.62%
Net CF	113,224,000
Next Earnings Date	2026-08-06
Open	21.07
Optionable	Yes
P FCF Ratio	22.44
P OCF Ratio	21.45
Position In Range	82.03
Post Close	21.6
Postmarket Change Percent	0.37
Postmarket Price	$21.68
Ppne	278,981,000
Pre Close	22.42
Price Date	2026-05-08
Ptbv Ratio	3.66
Relative Volume	1.75x
Revenue	638,783,000x
SBC By Revenue	15.76x
Share Based Comp	100,684,000
Tax By Revenue	0.53x
Tr6m	41.64%
Us State	California
Volume	4,831,624
Z Score	4.3

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does TXG pay a dividend?

Capital-return profile for this ticker.

Performance

TXG stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TXG?

Insider, institutional, and short-interest positioning.

Institutional ownership

+99.3%

Float: +90.7% of shares outstanding

Insider ownership

+7.8%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

TXG momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

47.3

Neutral momentum band

Price vs 200-day MA

+25.7%

50/200-day relationship not available

Beta (5Y)

2.05

More volatile than the market

Sharpe ratio

1.69

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TXG

Hub-level FAQ points readers to the deeper analysis pages.

What is the current TXG stock rating?

10x Genomics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full TXG analysis?

The full report lives at /stocks/TXG/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for TXG?

The latest report frames TXG around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the TXG page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.